Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 10/20 | 0.34 |
| ▸ | CA1 | P00915 | 10/20 | 0.34 |
| ▸ | CA2 | P00918 | 10/20 | 0.34 |
| ▸ | CA9 | Q16790 | 7/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19723141 | 0.89 | MEN1 (0.39) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL569003 | 0.87 | SERPINE1 (0.43) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL14541036 | 0.86 | MEN1 (0.38) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL14726004 | 0.86 | TDP1 (0.43) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL23674564 | 0.86 | SERPINE1 (0.41) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL19723041 | 0.84 | MEN1 (0.36) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL31758129 | 0.84 | MEN1 (0.42) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL10029064 | 0.82 | SYK (0.43) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL18361449 | 0.82 | SYK (0.43) | MEN1GAAKMT2ASERPINE1SYK | |
| SCHEMBL25189025 | 0.82 | SYK (0.43) | MEN1GAAKMT2ASERPINE1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4192831-B1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-11-14 | — | — | US | disclosed |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-2747570-B1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2018-09-19 | — | — | EP | disclosed |
| EP-2748155-B1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-9307766-B2 | Isoxazoline derivatives as insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9307766-B2 | Isoxazoline derivatives as insecticidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| US-20140194376-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-07-10 | — | — | US | disclosed |
| EP-2748155-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| EP-2747570-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013026695-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026931-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026933-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026929-A1 | DIHYDROPYRROLE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026931-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026933-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013026695-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192633-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MEN1 418/4885GAA 1010/4885KMT2A 4112/4885 |
| US-11897851-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, GCGR | MEN1 418/4885GAA 1010/4885KMT2A 4112/4885 |
| US-20140194376-A1 | ISOXAZOLINE DERIVATIVES AS INSECTICIDAL COMPOUNDS | CHRM1, CHRM2, CHRM3 | MEN1 2879/4885GAA 4047/4885KMT2A 1432/4885 |
| US-12528781-B2 | Heterocyclic GLP-1 agonists | GLP1R, GIPR, VIP | MEN1 1749/4885GAA 1396/4885KMT2A 3022/4885 |
| US-20240376061-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | MEN1 418/4885GAA 1010/4885KMT2A 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.